Investigational Site Number : 3800002

Florence, Firenze 50134

2 studies enrolling now · 2 studies all time

What they study most

Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Hemophilia

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B — Recruiting now